Lucas Svetlana
SEC insider (Form 3/4/5 filer). CIK 0001781292. Director at Jasper Therapeutics, Inc. (JSPR) and 2 other issuers. 9 reported Form 4/5 transactions since Sep 2024; latest on Jul 31, 2026. Located in REDWOOD CITY, CA.
Companies Lucas Svetlana has filed insider reports for
- Jasper Therapeutics, Inc. (JSPR): Director
- Scribe Therapeutics, Inc. (SCTX): Officer, Chief Business Officer
- aTYR PHARMA INC (ATYR): Director
Lucas Svetlana
CIK: 0001781292
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (9 total)
- Jul 31, 2026JSPR
Jasper Therapeutics, Inc.
AwardDirectStock Option (Right to Buy
7.5K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
PurchaseIndirect3K shares at avg. $15.00$45K - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
109.4K shares- - Jul 23, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectPerformance-based Stock Option (Right to Buy)
109.4K shares- - May 11, 2026ATYR
aTYR PHARMA INC
AwardDirectStock Option (right to buy)
50K shares- - Mar 13, 2026SCTX
Scribe Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
9.5K shares- - Sep 22, 2025JSPR
Jasper Therapeutics, Inc.
PurchaseDirect20K shares at avg. $2.43$49K - Jul 3, 2025JSPR
Jasper Therapeutics, Inc.
AwardDirectStock Option (right to buy)
7.5K shares- - May 1, 2025ATYR
aTYR PHARMA INC
AwardDirectStock Option (right to buy)
50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jul 31, 2026 |  JSPR Jasper Therapeutics, Inc. | Award Stock Option (Right to Buy | 7,500 | - | - | Direct |
| Jul 23, 2026 |  SCTX Scribe Therapeutics, Inc. | Purchase | 3,000 | $15.00 | $45,000 | Indirect |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award Stock Option (Right to Buy) | 109,426 | - | - | Direct |
| Jul 23, 2026 | SCTX Scribe Therapeutics, Inc. | Award Performance-based Stock Option (Right to Buy) | 109,426 | - | - | Direct |
| May 11, 2026 |  ATYR aTYR PHARMA INC | Award Stock Option (right to buy) | 50,000 | - | - | Direct |
| Mar 13, 2026 | SCTX Scribe Therapeutics, Inc. | Award Stock Option (Right to Buy) | 9,547 | - | - | Direct |
| Sep 22, 2025 | JSPR Jasper Therapeutics, Inc. | Purchase | 20,000 | $2.43 | $48,600 | Direct |
| Jul 3, 2025 | JSPR Jasper Therapeutics, Inc. | Award Stock Option (right to buy) | 7,500 | - | - | Direct |
| May 1, 2025 | ATYR aTYR PHARMA INC | Award Stock Option (right to buy) | 50,000 | - | - | Direct |
1-9 of 9 transactions